KRAS and non-small cell lung carcinoma: Another feasible approach to treat KRAS-mutated NSCLC might be to target the main signaling pathways controlled by the constitutively active mutant KRAS (i.e., the RAF-MEK-ERK or the PI3K/AKT/mTOR pathways).